EPCT-15. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

BACKGROUND: Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS: Patients (n=9) have received autologous tumor antigen-asso...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Grant, Melanie, Fortiz, Maria Fernanda, Wang, Lu, Lang, Haili, Datar, Anushree, Reynolds, Emily, Terpilowski, Madeline, Lazarski, Chris, Tanna, Jay, Pitino, Adriana, Zhang, Nan, Hoq, Fahmida, Hanley, Patrick, Kilburn, Lindsay, Packer, Roger, Rood, Brian, Bollard, Catherine, Hwang, Eugene
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Early Phase Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715090/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.137
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados